Document:

AGREEMENT

      THIS AGREEMENT is made and entered into as of this 24th day of February,
2005, by and between Interpharm, Inc., having its principal place of business at
75 Adams Avenue, Hauppauge, New York, 11788 ("Interpharm"), and Tris Pharma,
Inc., having its principal place of business at 2033 Route 130, Suite D,
Monmouth Junction, NJ 08852 ("Tris").

                                    RECITALS

      A. Interpharm is engaged in, among other things, the manufacture and
supply of finished drug products;

      B. Tris is engaged in, among other things, research and product
development of generic pharmaceutical products;

      C. Interpharm and Tris desire to establish a relationship pursuant to
which Tris will transfer research and technology to Interpharm which it will use
to develop and manufacture the pharmaceutical products listed herein; and

      D. Interpharm and Tris desire to establish a relationship pursuant to
which they will share the profits, if any, relating to the sale of the products
listed herein.

      In consideration of the foregoing premises, and the mutual covenants and
obligations set forth herein, Interpharm and Tris hereby agree as follows:

                                    ARTICLE I

                                   DEFINITIONS

      1.1 "Affiliate" shall mean any corporation or other entity which controls,
is controlled by, or is under common control with a party. A corporation or
other entity shall be regarded as in control of another corporation or entity if
it owns or directly or indirectly controls more than fifty percent (50%) of the
voting stock or other ownership interest of the other corporation or entity, or
if it possesses, directly or indirectly, the power to direct or cause the
direction of the management and policies of the corporation or other entity or
the power to elect or appoint more than fifty percent (50%) of the members of
the governing body of the corporation or other entity.

      1.2 "ANDA" shall mean the Abbreviated New Drug Application for a Product
filed with the FDA by Interpharm, and any supplements thereto.

      1.3 "API" shall mean the active pharmaceutical ingredient for a Product.

      1.4 "Award or Settlement" shall refer to any award or settlement that is
received by a Party in connection with a Tris Infringement Claim, Litigation
Costs, Judgment or other law suit or arbitration proceeding that is prosecuted
or defended by a Party with respect to any Product that exceeds, (i) in the case
of Tris, Tris Litigation Costs that have not been previously recovered by Tris
and (ii) in the case of Interpharm, Litigation Costs and Judgments that have not
been previously recovered by Interpharm. In the case where a Party receives
non-monetary consideration (such as future product rights, preferential pricing
arrangements, etc.) as part of such award or settlement, the fair market value
of such non-monetary compensation shall be included for purposes of this
definition; provided, however, that in the case where a Party seeks consent from
the other Party prior to entering into a settlement, the former Party, as part
of such consent request, must provide to the Party from which consent is sought
reasonably detailed information with respect to all of the proposed terms of the
award or settlement and, on the basis of such information, such other Party
must, prior to providing the consent sought, provide written notice advising the
Party seeking such consent that it believes that there is non-monetary
compensation involved in the proposed settlement in order to maintain any right
under this definition to add any value for non-monetary compensation. Should the
Parties be unable to reach agreement on the existence of or value of any
non-monetary compensation, the issue shall be submitted to binding arbitration
in accordance with the provisions of Section 8.2.

<PAGE>

      1.5 "Commercialization" shall mean all activities that are undertaken
during the term of this Agreement that relate to the use of Commercially
Reasonable efforts for the commercial manufacture, marketing, and sale of a
Product in the Territory, including advertising, education, planning, marketing,
promotion, distribution, market and product support studies for the Products in
the Territory.

      1.6 "Commercially Reasonable" shall mean a party's reasonable efforts and
diligence in accordance with its normal business, economic, legal, medical and
scientific judgment, taking into account the competitiveness of the marketplace,
the proprietary position of a Product, the regulatory structure involved, the
profitability of a Product, and other relevant factors including, without
limitation, technical, legal, scientific, medical, economic or other related
factors.

      1.7 "Competitive Product" means, with respect to any Product, the generic
AB rated product equivalent to the branded Product listed in Exhibit A.

      1.8 Confidential Information" shall mean, with respect to a party, all
information of any kind whatsoever (including without limitation, data,
compilations, formulae, models, patent disclosures, procedures, processes,
projections, protocols, results of experimentation and testing, specifications,
strategies and techniques), and all tangible and intangible embodiments thereof
of any kind whatsoever (including without limitation, apparatus, compositions,
documents, drawings, machinery, patent applications, records and reports), which
is disclosed by such party to the other party and is marked, identified as or
otherwise acknowledged to be confidential at the time of disclosure to the other
party, including all Product Details and this Agreement. Notwithstanding the
foregoing, Confidential Information of a party shall not include information
which the other party can establish by written documentation (a) to have been
publicly known prior to disclosure of such information by the disclosing party
to the other party, (b) to have become publicly known, without fault on the part
of the other party, subsequent to disclosure of such information by the
disclosing party to the other party, (c) to have been received by the other
party at any time from a source, other than the disclosing party, rightfully
having possession of and the right to disclose such information, (d) to have
been otherwise known by the other party prior to disclosure of such information
by the disclosing party to the other party, or (e) to have been independently
developed by employees or agents of the other party without the use of such
information disclosed by the disclosing party to the other party.

                                       2
<PAGE>

      1.9 "Development Costs" with respect to a Product, shall mean the costs
and expenses incurred by Interpharm in connection with obtaining an ANDA or
other Regulatory Approval for such Product, including, but not limited to, all
third party consultants retained through the development process, research and
development, pre-formulation, formulation, bio-equivalence, validation,
issuance, submission, costs and expenses of Third Party Experts incurred by
Interpharm in connection with the retention of a Third Party Expert with respect
to the Product Schedule or Product Details for a Product, and Other Development
Costs. With respect to all internal costs and expenses, (i) until the quarter
beginning July 1, 2007, (a) Interpharm shall provide quarterly estimates of such
costs to Tris and (b) shall provide annual statements of actual costs with a
reasonably detailed breakdown of such costs for each fiscal year ended June 30
and, (ii) beginning with the quarter ending September 30, 2007, Interpharm shall
provide the statement of actual costs referred to in (b) above on a quarterly
basis. In addition, (i) the statements referred to in (i)(b) and (ii) above
shall be binding on Interpharm in that, Interpharm acknowledges that it will not
change those numbers and (ii) such statements shall be subject to audit in
accordance with the provisions of Section 4.4.

      1.10 "Development Schedule" shall mean a reasonably detailed plan for
development of a Product, including delivery dates for the Product Details, the
scale-up, commencement of bioequivalency studies, submission and launch of the
Product, to the Project Management Committee and Interpharm.

      1.11 "Direct Labor and Benefits" shall mean that portion of basic wages,
labor and related payroll taxes and employee benefits spent in actual production
of a Product which can be identified with or charged to the Product.

      1.12 "Direct Sales" shall mean any sales of a Product by Interpharm or an
Interpharm Affiliate to a retail customer, wholesaler, distributors, repackager,
reseller, managed care organization, governmental entity or governmental agency.

      1.13 "Exempted Settlement" shall mean any settlement entered into by
Interpharm with respect to a Product (i) if, in Interpharm's good faith
judgment, Interpharm believes such settlement is necessary to avoid paying
Losses or (ii) after a Judgment has been rendered against Interpharm; provided,
that such Judgment is not limited solely to restricting Interpharm's ability to
Commercialize a Product.

      1.14 "DMF" shall mean the Drug Master File for the API for a Product, as
the same may be amended or supplemented from time to time, filed in the
Territory.

      1.15 "FDA" shall mean the United States Food and Drug Administration, and
any successor agency thereto.

      1.16 "GMP" shall mean current Good Manufacturing Practices promulgated by
the FDA.

      1.17 "Infringement Claim" shall mean any claim, legal action or lawsuit,
other than a Tris Infringement Claim, commenced by a third party against
Interpharm or Tris which in any way, directly or indirectly, relates to the
infringement of such party's intellectual property by a Product or the
Commercialization of a Product.

                                       3
<PAGE>

      1.18 "Initial Payment" shall mean payment of a total of $750,000 to be
made by Interpharm to Tris, inclusive of $375,000 received by Tris from
Interpharm prior to the date of this Agreement.

      1.19 "Intellectual Property Costs" shall mean all expenses incurred by
Interpharm, of any kind with respect to intellectual property relating to a
Product, including, but not limited to, legal, filings, investigation or
research or consultation with third-party experts, to the extent not included in
Litigation Costs.

      1.20 "Interpharm Award or Recovery" shall refer to any (i) Reimbursed
Insurance Recovery and (ii) Award or Settlement that is paid to Interpharm by a
third party other than Tris, and that is not affiliated with Interpharm or Tris.

      1.21 "Judgments" shall mean all judgments rendered against Interpharm or
an Interpharm Affiliate relating to an Infringement Claim or product liability
claim relating to a Product, including any interest, costs, attorneys' fees or
other monies awarded in connection with such judgments.

      1.22 "Litigation Costs" shall mean all actual costs and expenses,
including contingency fees or contingent arrangements, incurred by Interpharm in
connection with a Patent Challenge litigation relating to a Product, or in
connection with defending an Infringement Claim, including, but not limited to
attorneys' fees, expert witnesses, court costs and other related expenses.

      1.23 "Losses" shall mean any liabilities, damages, costs or expenses,
including reasonable attorney's fees, incurred by either party which arise from
any claim, lawsuit or other action by a third party.

      1.24 "Manufacturing Costs" shall mean, with respect to a Product, the
actual cost of manufacturing a Product, including the cost of Materials, Direct
Labor and Benefits, and Manufacturing Overhead, all determined in accordance
with U.S. Generally Accepted Accounting Principles. Manufacturing Costs shall
include, to the extent applicable, the cost to Interpharm of having some portion
or all of the Manufacturing Process performed by a third party. Interpharm shall
provide Tris with quarterly statements of Manufacturing Costs within sixty (60)
days of the end of each calendar quarter.

      1.25 "Manufacturing Overhead" shall include all operating expenses
incurred by and in support of the particular manufacturing cost centers,
purchasing department and quality assurance operations, with respect to a
Product, including indirect labor, related payroll taxes, employee benefits,
depreciation, taxes, insurance, rent, repairs and maintenance, supplies,
utilities, and factory administrative expenses. The allocable portion of the
operating expenses shall be determined by taking the total output of a Product
during the applicable period divided by Interpharm's total solid oral dosage
manufactured products and multiplying the result by the total amount of solid
oral dosage products manufacturing overhead for the applicable period.
Manufacturing Overhead shall exclude selling, general and administrative,
research and development, and, to the extent not included by Interpharm in cost
of goods sold, interest expenses and all debt service payments of Interpharm (it
being understood that only interest expenses and debt service payments which are
related to manufacturing may be included in Manufacturing Overhead).

                                       4
<PAGE>

      1.26 "Materials" means those items that form an integral and direct part
of a Product and are necessary for its production, as well as cartons, labels
and package inserts.

      1.27 "Net Profits" for each Product, shall mean the gross invoice sales of
such Product to third parties, collected by Interpharm, les the following
deductions:

            1.27.1 Manufacturing Costs;

            1.27.2 Insurance premiums related to such Product;

            1.27.3 The Sales and Marketing Deduction;

            1.27.4 Third Party Fees relating to such Product;

            1.27.5 any statutory or contractual liability for rebates to be paid
to any government entity, including but not limited to, rebates to be paid
pursuant to Medicaid rebate legislation and state and local government rebate
programs;

            1.27.6 cash discounts;

            1.27.7 any adjustments for allowances or credits for returned
Product, damaged Product, commercial rebates, promotional allowances given in
lieu of price adjustments, chargebacks, shelf stock adjustments, trade discounts
or any similar and then customary discounts, credits or adjustments, whether or
not such commercial rebates, or trade discounts are paid directly to the
customer;

            1.27.8 actual freight, shipping and insurance costs incurred by
Interpharm;

            1.27.9 any tax, excise or other government charge upon a Product or
measured by the production, sale, transportation or delivery of such Product;

            1.27.10 actual bad debts; and

            1.27.11 all costs incurred as the result of any recall, field
correction, market withdrawal, stock recovery, or other similar action with
respect to such Product. To the extent such costs are recovered by Interpharm,
they shall be added to Net Profits upon receipt by Interpharm.

      1.28 "Other Development Costs" with respect to a Product, shall mean all
legal expenses of any kind (including, but not limited to, any costs associated
with work performed by non-legal personnel and obtaining legal opinions)
incurred in connection with the development of a Product through in house
employees, outside counsel or consultants or third party services, that are not
otherwise included in Litigation Costs or Intellectual Property Costs. Other
Development Costs shall also include Intellectual Property Costs and any other
expenses incurred with respect to a Product that Interpharm determines were
necessary or advisable for the development of a Product.

                                       5
<PAGE>

      1.29 "Patent Challenge" shall mean an ANDA filed under in section
505(j)(2)(A)(vii) of the Federal Food, Drug and Cosmetic Act containing a
certification that a patent is invalid or will not be infringed by the
manufacture, use, or sale of the drug product for which the ANDA is submitted.

      1.30 "Product Details" shall mean all properties, Specifications and
formulations relating to a Product, including, specifications and formulations
of the API, and all properties, specifications, formulations and manufacturing
processes for the finished product necessary for a technology transfer of the
Product to Interpharm. Product Details shall not be considered complete until a
Product successfully passes a bioequivalence study. Product Details shall also
include such advice and counseling regarding information provided by Tris as may
be reasonably required by Interpharm.

      1.31 "Product Plan" shall mean a reasonably detailed plan to develop and
Commercialize a Product and delivery of Product Details to the Project
Management Committee, all actions necessary to obtain an ANDA or other
Regulatory Approval, including, but not limited to, research and development,
pre-formulation, formulation, bioequivalency, validation, submission,
pre-litigation, sales and marketing and regulatory approvals. With respect to
the Commercialization of a Product, the Product Plan shall include such sales
reports, annual sales forecasts, and sales and operations planning reports as
may be reasonably requested by the PMC or the representatives thereof of either
party. The Product Plan shall also encompass the following items which shall be
discussed by the Project Management Committee (but shall be decided by
Interpharm in the event that the PMC is unable to reach a consensus):

            1.31.1 Selecting the API suppliers (including auditing them) and
providing the APIs and related substances, impurities and technical
packages/dossiers of the Products; and

            1.31.2 Clinical studies and testing of the Products.

      1.32 "Products" shall mean the generic finished dosage pharmaceutical form
of the products listed on Exhibit A annexed hereto.

      1.33 "Project Management Committee" or "PMC" shall mean a committee
comprised of two representatives each from Interpharm and from Tris, who shall
review and discuss issues with respect to the Product Plan and Development
Schedule, and which shall meet regularly to discuss the progress of the
development of the Products, through and including Commercialization. At least
one of each party's representatives must be present at the meeting or by
telephone. To the extent that the PMC is required or otherwise empowered to make
any decision or take any action under the terms of this Agreement, unless
otherwise stated herein, in the event that the representatives of Interpharm and
Tris are unable to reach a decision, Interpharm shall have the right to make the
final decision. Notwithstanding the foregoing, or anything to the contrary
contained herein, Interpharm may, at its sole and absolute discretion, make,
and/or override any and all decisions to be made by the PMC hereunder, and, (i)
if the Interpharm representatives have attempted to call a meeting of the PMC at
least twice with at least five (5) days notice and, (ii) in each case, the Tris
representatives have not attended such meeting, make any decision regardless of
whether a meeting of the PMC has been held with respect to such decision.

                                       6
<PAGE>

      1.34 "Quarterly Payments" shall mean a series of payments from Interpharm
to Tris every ninety (90) days beginning on the ninetieth day after the Initial
Payment until the Tris Total Payments equal $3,750,000. Each Quarterly Payment
shall be $400,000, except for the final Quarterly Payment, which shall be
$200,000.

      1.35 "Regulatory Approval" shall mean the ANDA or other approvals,
licenses, registrations, or authorizations of any Regulatory Authority,
necessary for the manufacture, use, storage, import, transport and sale of a
Product in the Territory.

      1.36 "Regulatory Authority" shall mean any governmental department, agency
or regulatory body responsible for issuing a Regulatory Approval and/or
monitoring or enforcing applicable laws, regulations and rules with respect to
the sale and manufacture of pharmaceutical products.

      1.37 "Reimbursed Insurance Recovery" shall mean any recovery of insurance
proceeds by a Party, on account of a Tris Infringement Claim, Litigation Costs
or Judgment that (i) in the case of Tris, are in respect to Tris Litigation
Costs that have not been previously recovered by Tris and (ii) in the case of
Interpharm, are in respect to Litigation Costs or Judgments that have not been
previously recovered by Interpharm.

      1.38 "Sales and Marketing Deduction" for each Product, shall mean three
percent (3%) of the gross invoice sales of such Product.

      1.39 "Set Aside" shall mean an amount of money equal to ten percent (10%)
of the Net Profits earned with respect to a Product which is to be used solely
to repay and/or reimburse Interpharm and Tris as set forth elsewhere in this
Agreement.

      1.40 "Specifications" shall mean the specifications required to obtain an
ANDA and/or Regulatory Approvals for a Product based on an NDA or other
specifications of an innovator product and as contained in the DMF for the API
unless changes are required as described in the United States or other
applicable Pharmacopoeia, as such specifications may be amended at the request
of the FDA or other applicable Regulatory Authority or by mutual agreement of
the Parties from time to time.

      1.41 "Territory" shall mean the United States, and its territories and
possessions, including Puerto Rico.

      1.42 "Third Party Expert" shall mean any pharmaceutical expert designated
by either of the Parties to provide advice with respect to any issues relating
to any Development Schedule or Product Details. The cost of any Third Party
Experts shall be paid by the retaining party but shall then be reimbursed from
the Set Aside.

                                       7
<PAGE>

      1.43 "Third Party Fees" shall mean, with respect to any Product, all fees
of any kind incurred by Interpharm whether through its own employees or to a
third party to continue or assist with development of a Product in the event of
a Product Failure (as defined in Section 2.10 below), including, but not limited
to Interpharm hiring an employee for such purpose, delegating one or more
employees, or Interpharm making payments of cash or profit sharing or royalties
to a third party. For the purpose of clarity, (i) Third Party Fees shall not
include any expenses which would have been paid by Interpharm with respect to a
Product pursuant to the terms of this Agreement had there not been a Product
Failure; and (ii) no Third Party Fees shall be included in the definition of
Development Costs.

      1.44 "Total Tris Payments" shall mean the Initial Payment plus the total
of all Quarterly Payments as of a particular date.

      1.45 "Tris Award or Recovery" shall refer to any (i) Reimbursed Insurance
Recovery and (ii) Award or Settlement that is paid to Tris by a third party
other than Interpharm, and that is not affiliated with Tris or Interpharm.

      1.46 "Tris Infringement Claim" shall mean any legally actionable claim
which arises from another party's infringement of any Tris Intellectual
Property.

      1.47 "Tris Intellectual Property" shall mean any patent owned or held by
Tris which relates to a Product or is part of the Product Details.

      1.48 "Tris Litigation Costs" shall mean all actual and reasonable costs
and expenses incurred by Tris in connection with a Tris Infringement Claim.

      1.49 "Tris Reimbursable Set Aside" shall mean, with respect to any
Product, the Second Source Cost for such Product and the cost incurred by Tris
in connection with the retention of a Third Party Expert with respect to the
Development Schedule or Product Details for a Product.

                                   ARTICLE II

             DEVELOPMENT; COOPERATION; PROJECT MANAGEMENT COMMITTEE

      2.1. Development Overview. The following provisions relate to the overall
responsibility of the parties and the PMC for the development of the Products:

            2.1.1 Tris shall be responsible for delivery of all Product
Schedules and Product Details for the Products to the PMC. Tris shall deliver
the Development Schedule for each Product by April 1, 2005. The development of
each Product and the Product Plan, shall be reviewed by the PMC. During the
development and regulatory review of a Product, the PMC shall meet at the call
of either Party, and as required under this Agreement, at a mutually acceptable
location, or by telephone. Each Party shall bear its own costs with respect to
participation in the PMC. Once the Product Details are received by the PMC, the
PMC shall review and discuss: (i) all development decisions regarding the
Product, including, but not limited to, clinical trials and Regulatory
Approvals, Patent Challenges and (ii) deciding whether to defend, and the
defense of, Infringement Claims.

                                       8
<PAGE>

            2.1.2 In the case of any potential patent litigation (including any
litigation arising in connection with a Patent Challenge), Interpharm shall keep
the PMC apprised of (i) whether it will defend an Infringement Claim and the
defense of such claim, and whether it will prosecute, and prosecution of, a Tris
Infringement Claim and (ii) whether it will proceed with, and/or proceeding
with, a Patent Challenges.

            2.1.3 In the case of a Tris Infringement Claim, if Interpharm elects
not to prosecute such a Claim, Tris shall have the right to prosecute the Claim
on its own. In that event, (i) Tris shall keep Interpharm reasonably apprised of
the progress and status thereof on an ongoing basis; and (ii) Tris shall have
the right to recover the Tris Litigation Costs associated with such litigation
in accordance with Section 3.1.1, below; provided, however, that (i) such
litigation relates to one or more Products, and (ii) the infringement underlying
the Tris Infringement Claim would adversely affect Interpharm's
Commercialization of a Product.

      2.2 Development Schedules. By April 1, 2005, Tris shall deliver to the PMC
and Interpharm the Development Schedule for each Product for their review and
for Interpharm's approval. In the event that Interpharm shall not approve the
Development Schedule for a Product, Tris and Interpharm shall meet and in good
faith discuss the reasons for the failure to approve and a method to resolve the
basis for non-approval. In the event that the Parties are unable to agree on a
method to resolve the basis for non-approval, Interpharm shall provide to Tris a
written explanation of the reasons for disagreement. Thereafter, each Party
shall have the right to retain a Third Party Expert to assist in the evaluation
of the issue in dispute. In such event, the Third Party Experts shall provide to
each Party's representative on the PMC their recommendation and analysis on such
disputed issue in writing, including a reasonably detailed explanation for such
decision. Interpharm mayconsider the recommendations of the Third Party Experts
but shall have the right to make the final decision with respect to such issue
in its sole and absolute discretion. The parties shall make a good faith effort
to resolve the issue in dispute within thirty (30) days (from the point that the
dispute arose).

      2.3 Product Details. Within thirty (30) days prior to the dates for final
delivery of the Product Details for each Product, Tris shall submit such Product
Details to the PMC and to Interpharm for their review and Interpharm's approval.
In the event that Interpharm shall not approve the Product Details for a
Product, Tris and Interpharm shall meet and in good faith discuss the reasons
for the failure to approve and a method to resolve the basis for non-approval.
In the event that the Parties are unable to agree on a method to resolve the
basis for non-approval, Interpharm shall provide to Tris a written explanation
of the reasons for disagreement. Thereafter, each Party shall have the right to
retain a Third Party Expert to assist in the evaluation of the issue in dispute.
In such event, the Third Party Experts shall provide to each Party's
representative on the PMC their recommendation and analysis on such disputed
issue in writing, including a reasonably detailed explanation for such decision.
Interpharm may consider the recommendations of the Third Party Experts but shall
have the right to make the final decision with respect to such issue in its sole
and absolute discretion.

                                       9
<PAGE>

      2.4 Regulatory Approvals and Launch. Upon delivery by Tris of final
Product Details approved by Interpharm, Interpharm shall use its Commercially
Reasonable efforts to obtain Regulatory Approval and Commercialize the Products.

      2.5 Commercialization of Products; PMC Review and Input. Following the
launch of a Product, the PMC shall:

            2.5.1 monitor the progress and results of the marketing, sale and
distribution of the Product;

            2.5.2 review and discuss the sales and operations plans for such
Product; and

            2.5.3 monitor and discuss the competitive dynamics of the market for
the Product and the ongoing financial viability of the Product;

it being understood, however, that, except as qualified in Section 2.6 below,
Interpharm shall have the final decision-making authority with respect to such
Commercialization issues.

      2.6 Loss Leader. Interpharm shall not sell a Product as a loss leader, or
otherwise cause its or an Affiliate's sales of another product to benefit at the
expense of a Product. For purposes of this Section 2.6, the term "loss leader"
shall refer to a situation in which a Product is sold for the primary purpose of
benefiting sales of one or more products other than Products on terms that are
materially less favorable than terms that could otherwise have been obtained if
the Product had not been sold for such purpose.

      2.7 Exclusivity.

            2.7.1 Tris' Exclusivity Obligation. Tris shall not cooperate with
any other person or entity with respect to the manufacture, supply or
distribution of a Product in the Territory without the prior written consent of
Interpharm during the term of this Agreement. For the avoidance of doubt, Tris
may not provide Product Details for a Product to any person or entity outside
the Territory if such person or entity intends to, or will sell Products in the
Territory. Tris shall take Commercially Reasonable steps to ensure that other
parties do not sell Products in the Territory, including, but not limited to,
requiring such other parties to agree not to do so and taking Commercially
Reasonable actions to enforce such agreements. In the event that Products or
Product Details are sold in the Territory in contravention of this Agreement,
Tris hereby agrees that it shall pay over to Interpharm the greater of all
profits earned with respect to such Products and Product Details or the amount
of Interpharm's lost profits as determined by the amount of Products sold in
contravention of this Section.

            2.7.2 Interpharm's Exclusivity Obligation.

                  2.7.2.1 Interpharm hereby covenants not to in-license, market,
sell, distribute or have marketed, have sold or have distributed any Competitive
Product in the Territory during the Term. Notwithstanding the foregoing, if
Interpharm or an Interpharm Affiliate acquires an entity or all or substantially
all of the assets of an entity and such assets include, a Competitive Product,
Interpharm shall use its Commercially Reasonable efforts to divest itself of
such Competitive Product within one-hundred and twenty (120) days of the closing
of such acquisition (subject to any binding commitments to customers), if such
Competitive Product is not being sold commercially at such time. If, however,
any sales of a Competitive Product are made, Tris shall be entitled to payment
by Interpharm of Net Profits (determined on the same basis under this Agreement
as in the case of the sale of the Product to which the Competitive Product
relates) from the sales of such Competitive Product.

                                       10
<PAGE>

                  2.7.2.2 Interpharm hereby covenants that it will not, without
the prior written authorization of Tris, utilize the Product Details delivered
hereunder to: (i) promote or actively solicit sale of a Product or advertise a
Product, outside of the Territory; (ii) purchase or cause to be purchased a
Product which Interpharm has represented, directly or indirectly, as being for
the purpose of sale in the Territory for sale in any other country outside the
Territory; or (iii) knowingly sell or distribute for resale a Product purchased
hereunder to a third party who intends to sell outside of the Territory.

                  2.7.2.3 Interpharm hereby covenants that, except with respect
to an Exempted Settlement, it will not assign, waive or license to a third
party, any exclusivity rights that it may have with respect to a Product without
the written consent of Tris.

      2.8 The Parties' Responsibilities.

            2.8.1 Interpharm's Responsibilities. In addition to its
responsibilities set forth above, Interpharm shall be responsible for:

                  2.8.1.1 Making the following payments to Tris. In the event
that Interpharm fails to make any of the following payments, Tris's sole remedy
shall be the commencement of an arbitration in accordance with Section 8.2:

                        2.8.1.1.1 the Initial Payment; and

                        2.8.1.2.2 the Quarterly Payments.

                  2.8.1.2 Testing of API samples for the microbial samples
during development.

                  2.8.1.3 Payment for all clinical studies and testing of the
Products.

                  2.8.1.4 Supplying to Tris samples of the branded, and if
applicable, generic, versions of the Products which Tris is requested to
develop.

                  2.8.1.5 Obtaining and maintaining all necessary Regulatory
Approvals.

                  2.8.1.6 Obtaining all applicable regulatory state and local
approvals for the manufacture of Product, for filing all periodic reports and
notifications as required by the regulatory authorities and for instituting and
maintaining such stability and sample retention programs as are required by
applicable law.

                                       11
<PAGE>

                  2.8.1.7 At the written request of Tris, delivered at any time
following the receipt of tentative or final approval of the ANDA, using
Commercially Reasonable efforts to amend or supplement, as the case may be, the
ANDA for a Product to qualify a second production source ("Second Source");
provided, however, that such qualification does not, as determined by
Interpharm, in good faith, interfere with final Regulatory Approval or
Commercialization of a Product. The costs of any such qualification ("Second
Source Costs") shall be paid by Tris but shall then be recoverable by Tris from
the Set Aside.

                  2.8.1.8 The Commercialization of a Product in the event that
all necessary Regulatory Approvals are obtained; provided, however, that in the
event of a Patent Challenge with respect to a Product, Interpharm shall have no
obligation for Commercialization of the Product unless and until one hundred
eighty (180) days have passed since the later of (i) a favorable final
non-appealable appellate decision with respect to the Patent Challenge and (ii)
final Regulatory Approval. Notwithstanding the foregoing, Interpharm shall
obtain Tris' written consent, which consent shall not be unreasonably withheld,
(i) in the event that Interpharm wishes to assign, license or waive its right to
market or distribute a Product or (ii) market or distribute such Product other
than through Direct Sales. In addition, in the event that there is a pending
litigation relating to a Product at the time of Commercialization or if
Interpharm reasonably believes it would not be Commercially Reasonable to
Commercialize a Product (a "Marketing Halt") of the threat of litigation,
Interpharm shall have no obligation to Commercialize such Product. A Marketing
Halt shall not result in a Production Cut-Off, as defined below. In the event of
a Marketing Halt, Interpharm shall promptly provide written materials to Tris
supporting its decision for a Marketing Halt, including, but not limited to,
materials from inside and outside counsel to Interpharm to the extent that the
disclosure of the materials will not waive any applicable privilege.

                  2.8.1.9 Interpharm shall manufacture, fill, package, label and
warehouse a Product in conformity with GMP, the ANDA and all applicable laws and
regulations; provided, however, that if Interpharm determines, in its sole and
absolute discretion, that it no longer wishes to manufacture and supply a
Product (a "Production Cut-off"), it may cease doing so with no penalty
hereunder, provided, however, that Interpharm must provide written notice to
Tris immediately upon making its decision to effect a Production Cut-off. If
Interpharm has not resumed manufacturing and selling the Product within ninety
(90) days thereafter, and confirmed that fact in writing to Tris, Tris shall
have the right to have the Product manufactured at a Second Source and to sell
and distribute, or arrange for the sale and distribution of, such Product
manufactured by such Second Source. All net profits generated form the sale of a
Product manufactured by such Second Source shall be split between the Parties
equally. Notwithstanding the delivery of a Production Cut-off notice, Interpharm
shall have the right to resume manufacturing and selling the Product on a
non-exclusive basis (on the same Net Profit split as before) upon the delivery
of written notice from Interpharm to Tris. For the purpose of clarity, a
Production Cut-Off shall not result from a Marketing Halt and shall only result
from a situation where Interpharm has the ability to produce and market a
Product on Commercially Reasonable terms, and without violating any law or
regulation, but chooses not to do so.

                  2.8.1.9 Payment of all costs of a Patent Challenge.

                                       12
<PAGE>

                  2.8.1.10 Performing an analysis of all Products to determine
whether a Product will infringe on the intellectual property of another party
(an "IP Analysis"). Interpharm shall perform an IP Analysis after receipt from
Tris of the Product Details for a Product. In the event that Interpharm
determines that a Product, as formulated in the Product Details, infringes the
intellectual property of another party, it shall provide written notice, along
with written materials supporting its analysis, and shall make its counsel
available to discuss such analysis with Tris' counsel. Interpharm shall have no
obligation to disclose any written materials that would result in the waiver of
any privilege. Notwithstanding the foregoing, in the event that the Parties do
not resolve the infringement issue within thirty (30) days of the receipt of the
written notice set forth in the previous sentence, Interpharm may, in its sole
and absolute discretion, require that Tris reformulate the Product and Tris
shall use its Commercially Reasonable best efforts to do so.

                  2.8.1.11 Keeping the Project Management Committee apprised of
all litigation relating to the Products and all IP Analyses.

      2.9 Tris's Responsibilities. In addition to the responsibilities set forth
above, Tris shall be responsible for:

            2.9.1 payment of all costs for research and development and
developing the Product Details with respect to a Product;

            2.9.2 keeping thorough and accurate records, in a good scientific
manner and, to the extent reasonably practicable, in separate laboratory
notebooks distinct from other work being conducted by Tris, of all activities in
connection with the development of the Products and, on reasonable notice,
making such records available to Interpharm. All such records shall be deemed to
be confidential information under Article VII, below;

            2.9.3 maintaining the Tris Intellectual Property; and

            2.9.4 deciding whether to prosecute a Tris Intellectual Property
Claim of which Tris becomes aware and which is not otherwise being prosecuted
under the terms of this Agreement.

      2.10 Failure of or Failure to Deliver Product Details. In the event that
Tris shall fail to deliver a Product Schedule or any Product Details in
accordance with the terms of this Agreement, or the Product Details for a
Product fail to meet the requirements set forth in this Agreement (a "Product
Failure"), Interpharm may continue development of the Product using such
portions of the Product Details that have been delivered and can be used. In the
case where Interpharm elects to continue development of such Product, it may do
so in any manner that it, in its sole and absolute discretion, deems
appropriate, including, without limitation, hiring employees internally,
delegating responsibilities to existing employees and having a third party
conduct the needed work.

                                       13
<PAGE>

                                   ARTICLE III

                 PROFIT SHARING, EXPENSE RECOVERY AND SET ASIDE

      3.1. Profit Sharing. The Parties hereby agree, that for the purpose of
clarity, Net Profits shall be calculated for _____________separate from all
other Products as a group.

            3.1.1 Calculation of Net Profits.

                  3.1.1.1 Prior to any allocation and distribution or Set Aside
of Net Profits to the Parties in accordance with the remainder of this Article
III, one third (1/3) of Net Profits from all Products under this Agreement as a
whole shall be allocated for the recovery of Litigation Costs, Judgments, Losses
and Tris Litigation Costs as set forth hereafter ("Allocated Recovery Costs").
Allocated Recovery Costs shall be paid to each Party pro rata based on each
Party's share of the aggregate of all unreimbursed Litigation Costs, Judgments,
Losses and Tris Litigation Costs. For the sake of clarity, Allocated Recovery
Costs shall only be paid to a Party to the extent that such Party has
unreimbursed Allocated Recovery Costs that have been previously incurred.

                  3.1.1.2 Any Tris Award or Recovery relating to a Product shall
be deducted dollar for dollar against any amounts owed to Tris pursuant to this
Article III as of the time collected or when any non-monetary benefit referred
to in Section 1.4 is realized.

                  3.1.1.3 Any Interpharm Award or Recovery relating to a Product
shall be added to Net Profits for such Product for purposes of this Article III
at the time collected or when any non-monetary benefit referred to in Section
1.4 is realized.

            3.1.2 _____________.

                  3.1.2.1 Set Aside. With respect to _____________, the Set
Aside shall be distributed to the Parties pro rata based on each Party's share
of the aggregate of all of the Initial Payment, Development Costs and the Tris
Reimbursable Set Aside for _____________until the aggregate of the Set Aside for
_____________is equal to the sum of the Initial Payment plus all Development
Costs plus the Tris Reimbursable Set Aside relating to _____________.

                  3.1.2.2 Profit Distribution. After the Set Aside, each Party
shall be entitled to 50% of the remaining Net Profits, if any, from the sales of
__________.

            3.1.3 Other Products.

                  3.1.3.1 Set Aside. With respect to all Products other than
_____________("Non-DS Products"), the Set Aside shall be distributed to the
Parties pro rata based on each Party's share of the aggregate of all of the
Quarterly Payments, all Non-DS Product Development Costs and the non-DS Product
Tris Reimbursable Set Aside for the Non-DS Products until the aggregate of the
Set Aside for the Non-DS Products is equal to the sum of the Quarterly Payments
plus all Non-DS Product Development Costs plus the Non-DS Products Tris
Reimbursable Set Aside.

                  3.1.3.2 Profit Distribution. After the Set Aside, each Party
shall be entitled to 50% of the remaining Net Profits, if any, from the sales of
Non-DS Products.

                                       14
<PAGE>

                  3.1.4 Distribution of Net Profits. Within ten (10) business
days of the end of each month, Interpharm shall provide to Tris a calculation of
the Net Profits due to it based on monies actually collected and received by it
(the "Net Profit Statement") along with the payment of Tris' share of Net
Profits due. In the event that Interpharm fails to make any payment of Net
Profits, Tris's sole remedy shall be the commencement of an arbitration in
accordance with Section 8.2.

                                   ARTICLE IV

                       FURTHER OBLIGATIONS OF THE PARTIES

      4.1. Regulatory File Maintenance. Interpharm shall be solely responsible
for maintaining the ANDA and all other applicable FDA approvals and
registrations to permit the sale of Product.

      4.2. Facility Qualification. Interpharm shall take all Commercially
Reasonable actions to qualify (and thereafter to maintain qualification of the
facility (or facilities) at which Interpharm will manufacture Product hereunder,
as required under applicable law.

      4.3. Adverse Reactions; Recall. In the event Interpharm believes it may be
necessary to conduct a recall, field correction, market withdrawal, stock
recovery, or other similar action with respect to a Product (a "Recall"),
Interpharm shall have sole discretion to make all decisions with respect to such
events. Any and all costs related to a Recall shall be borne by Interpharm.

      4.4 Audit Rights Tris shall have the right at any time and from time to
time to nominate a firm of independent certified public accountants to have
access to the financial records of Interpharm relating to Products to verify, at
Tris' expense, Net Profits. In the event that the auditing accountant finds that
Interpharm's calculation of Net Profits, varies from the actual amounts by more
than five percent (5%), Tris shall provide Interpharm with notice of the
variance. Interpharm shall have thirty (30) days from the receipt of such notice
to analyze the variance. At the conclusion of the thirty (30) say period,
Interpharm shall either (i) pay the cost of that audit and any monies owed as a
result of the variance with interest at five percent (5%) per annum on such
amount for the period of time that the variance existed or (ii) provide Tris
written notice of any disagreement Tris' position (the "Interpharm Notice"). In
the event that Tris disagrees with the Interpharm Notice, then Tris's sole
remedy shall be commencement of an arbitration in accordance with Section 8.2.

                                    ARTICLE V

                    REPRESENTATIONS, WARRANTIES AND COVENANTS

      5.1. Representations and Warranties by each Party. Each Party hereby
represents and warrants to the other party as follows:

            5.1.1 Corporate Existence. Such Party is a corporation duly
organized, validly existing and in good standing under the laws of the
jurisdiction in which it is incorporated.

                                       15
<PAGE>

            5.1.2 Authorization and Enforcement of Obligations. Such party (a)
has the corporate power and authority and the legal right to enter into this
Agreement and to perform its obligations hereunder, and (b) has taken all
necessary corporate action on its part to authorize the execution and delivery
of this Agreement and the performance of its obligations hereunder. This
Agreement has been duly executed and delivered on behalf of such party, and
constitutes a legal, valid, binding obligation, enforceable against such party
in accordance with its terms.

            5.1.3 No Conflict. The execution and delivery of this Agreement and
the performance of such party's obligations hereunder (a) do not conflict with
or violate any requirement of applicable laws or regulations, and (b) do not
conflict with, or constitute a default under, any material contractual
obligation of such party.

      5.2 Additional Representations, Warranties and Covenants by Tris. Tris
hereby represents, warrants and agrees with Interpharm that all Product Details
provided to, and to be provided to Interpharm, are and will be true and accurate
in all respects and will include use of only pharmaceutically accepted products
listed in the IIG Guide or GRAS (Generally Recognized as Safe) products.

                                   ARTICLE VI

                        LICENSE AND INTELLECTUAL PROPERTY

      6.1. License. Tris hereby grants to Interpharm a royalty free license in
the Territory to use all technology, discoveries, patent applications, patents,
ANDAs, know-how and inventions relating to a Product or any Product Details
("Tris Intellectual Property") for a Product (the "License"). Interpharm may use
or exploit the License for any purpose whatsoever, provided, however, that
Interpharm may not use any patented Tris Intellectual Property for any purpose
other than for the Products.

                                   ARTICLE VII

                      CONFIDENTIALITY AND PUBLIC DISCLOSURE

      7.1. Confidentiality. Except for literature and information intended for
disclosure to customers, and except as may be required to obtain government
approval to manufacture, sell or use a Product, or as may be required under
applicable federal securities laws, each Party will treat as confidential the
Confidential Information, and will take all necessary precautions to assure the
confidentiality of such information. Each party agrees to return to the other
party upon the expiration or termination of this Agreement all Confidential
Information acquired from such other party, except as to such information it may
be required to retain under applicable law or regulation, and except for one
copy of such information to be retained by such party's legal department or
outside counsel. Neither Party shall, during the period of this Agreement or for
five (5) years thereafter, without the other party's express prior written
consent use or disclose any such Confidential Information for any purpose other
than to carry out its obligations hereunder. Each Party, prior to disclosure of
such Confidential Information to any employee, consultant or advisor shall
ensure that such person is bound in writing to observe the confidentiality
provisions of this Agreement. The obligations of confidentiality shall not apply
to information that the receiving party is required by law or regulation to
disclose, provided however that the receiving party shall so notify the
disclosing party of its intent and cooperate with the disclosing party on
reasonable measures to protect the confidentiality of the information.

                                       16
<PAGE>

      7.2. Public Disclosure. Except for such disclosure as is deemed necessary,
in the reasonable judgment of a Party, to comply with applicable laws, no
announcement, news release, public statement, publication, or presentation
relating to the existence of this Agreement, the subject matter hereof, or
either Party's performance hereunder will be made without the other Party's
prior written approval, which approval shall not be unreasonably withheld. The
Parties agree that they will use reasonable efforts to coordinate the initial
announcement or press release relating to the existence of this Agreement so
that such initial announcement or press release by each is made
contemporaneously.

                                  ARTICLE VIII

                      TERM; ARBITRATION OF CERTAIN DISPUTES

      8.1. Term. Unless sooner terminated as provided in this Agreement, this
Agreement shall remain in effect as long as Interpharm continues to sell any of
the Products.

      8.2 Arbitration Procedure. The Parties hereby agree that only Sections
2.8.1.1, 3.1.1, 3.1.4 and 4.4 of this Agreement shall be subject to arbitration.
Any arbitration shall be conducted in accordance with the following provisions:

            8.2.1 Any Party seeking to commence an arbitration hereunder shall
send a written notice providing the facts underlying the potential arbitration
to the other Party. The Parties shall then make a good faith effort to settle
the dispute. In the event that the dispute is not settled within thirty (30)
days of delivery of the notice, the Party that delivered the notice may commence
an arbitration hereunder;

            8.2.2 Arbitrations shall be conducted in accordance with the
Commercial Rules of the American Arbitration Association ("AAA") by three
arbitrators at a AAA facility in New York City;

            8.2.3 The costs of the arbitration and of the Parties in conducted
the arbitration, including reasonable attorneys' fees, shall be borne by the
losing Party;

            8.2.4 Upon and after the submission of any dispute to arbitration,
the Parties shall continue to exercise their remaining respective rights, and
fulfill their remaining respective obligations under this Agreement;

            8.2.5 Any arbitration award rendered in accordance with the
provisions of this Section 8.4 shall be final and binding upon the concerned
Parties, and the Parties further agree that such award may be enforced by any
court having jurisdiction over the Party against which the award has been
rendered or the assets of such Party wherever the same may be located. The
arbitrators shall be instructed that any such arbitration shall be completed and
an arbitration award issued within three (3) months following the commencement
thereof.

                                       17
<PAGE>

      8.3 Liquidated Damages. In the event that Interpharm fails to pay a final
arbitration award in favor of Tris within thirty (30) days of the rendering of
the final award, Interpharm shall pay to Tris liquidated damages of $20,000 in
addition to the award. The Parties acknowledge and agree that the sums payable
hereunder are liquidated damages and not penalties. The parties further
acknowledge that (i) the amount of loss or damages likely to be incurred by Tris
is incapable or is difficult to precisely estimate, (ii) the amounts specified
bear a reasonable proportion and are not plainly or grossly disproportionate to
the probable loss likely to be incurred by Tris in the event that a final
arbitration award is not paid promptly, and (iii) the Parties are sophisticated
business parties and have been represented by sophisticated and able legal
counsel and negotiated this Agreement at arm's length.

      8.4 Termination by Either Party for Cause. This Agreement may be
terminated prior to the expiration of the Term by either Party if the other
Party is subject to a Chapter 7 or other liquidation bankruptcy, dissolution or
winding-up of operations (other than dissolution or winding up for the purposes
or reconstruction or amalgamation)

      8.5 Effect of Termination.

            8.5.1 Upon termination of the Agreement by Tris with respect to a
particular Product, the following shall occur:

                  8.5.1.1 All rights and licenses granted to Interpharm for such
particular Product shall terminate immediately;

                  8.5.1.2 Interpharm shall have no further rights hereunder in
the particular Product, and the ANDA for such Product shall revert and be
transferred to Tris, subject to Interpharm's option to sell off existing
inventory of such particular Product for two (2) years after the termination
date;

            8.5.2 Upon termination of the Agreement by Interpharm, the following
shall occur:

                  8.5.2.1 All future payment obligations to Tris shall terminate
immediately, other than the obligation to pay any amounts that were due and
owing prior to the date of termination;

                  8.5.2.2 Interpharm shall have the unrestricted right to
manufacture and sell the Products in the Territory on a royalty-free basis.

            8.5.3 Expiration or termination of this Agreement shall not relieve
the Parties of any obligation, including any payment obligation, accruing prior
to such expiration or termination. .

            8.5.4 Within thirty (30) days following the expiration or
termination of this Agreement, the non-terminating Party shall return to the
other Party, or destroy, upon the written request of the other Party, any and
all Confidential Information of the other Party in its possession and upon a
Party's request, such destruction (or delivery) shall be confirmed in writing to
such Party by a responsible officer of the other Party.

                                       18
<PAGE>

                                   ARTICLE IX

                                 INDEMNIFICATION

      9.1 Indemnification.

            9.1.1 Tris Indemnification. Tris agrees to indemnify, defend and
hold Interpharm harmless from and against any Losses resulting from or arising
out of the execution by Tris of this Agreement, the performance or breach by
Tris of its representations, warranties, covenants or obligations under this
Agreement, failure by Tris to take any action required to be taken by it (and
not by Interpharm) hereunder, at law or otherwise, or its negligence or willful
misconduct in the performance of its obligations hereunder. Tris shall also
indemnify Interpharm with respect to any Losses relating to a Product
manufactured by a Second Source.

            9.1.2 Interpharm Indemnification. Interpharm agrees to indemnify,
defend and hold Tris harmless from and against any Losses resulting from or
arising out of (i) Interpharm's breach of its representations, warranties,
covenants or obligations under this Agreement, (ii) any act of Interpharm or
failure by Interpharm to take any action required to be taken by it (and not by
Tris) hereunder, at law or otherwise, (iii) infringement on the intellectual
property of a third party, or, subject to Tris's performance of Section 5.2,
(iv) any injuries caused by (a) the manufacture, storage, packaging, handling,
marketing or distribution of a Product, or (b) the failure to warn of the risks
associated with a Product; provided, however, that all of the indemnification
obligations under this Section 9.1.2 shall not apply to any Product that is
manufactured by the Second Source)

            9.1.3 A Party seeking indemnification ("Indemnified Party") shall
notify, in writing, the other party ("Indemnifying Party") within fifteen (15)
days from the assertion of any claim or discovery of any fact upon which the
Indemnified Party intends to base a claim for indemnification. An Indemnified
Party's failure to so notify the Indemnifying Party shall not, however, relieve
such Indemnifying Party from any liability under this Agreement to the
Indemnified Party with respect to such claim except to the extent that such
Indemnifying Party is actually denied, during the period of delay in notice, the
opportunity to remedy or otherwise mitigate the event or activity(ies) giving
rise to the claim for indemnification and thereby suffers or otherwise incurs
additional liquidated or other readily quantifiable damages as a result of such
failure. The Indemnifying Party, while reserving the right to contest its
obligations to indemnify hereunder, shall be responsible for the defense of any
claim, demand, lawsuit or other proceeding in connection with which the
Indemnified Party claims indemnification hereunder. The Indemnified Party shall
have the right at its own expense to participate jointly with the Indemnifying
Party in the defense of any such claim, demand, lawsuit or other proceeding,
but, except as otherwise provided below in this Section 9.1, with respect to any
issue involved in such claim, demand, lawsuit or other proceeding with respect
to which the Indemnifying Party has acknowledged its obligation to indemnify the
Indemnified party hereunder, the Indemnifying Party shall have the right to
select counsel, settle, try or otherwise dispose of or handle such claim,
demand, lawsuit or other proceeding on such terms as the Indemnifying Party
shall deem appropriate, subject to any reasonable objection of the Indemnified
Party.

                                       19
<PAGE>

            9.1.4 The Indemnifying Party shall have the right to settle or
compromise any claim against the Indemnified Party without the consent of the
Indemnified Party provided that the terms thereof: (a) provide for the
unconditional release of the Indemnified Party; (b) require the payment of
compensatory monetary damages by Indemnifying Party only; and (c) expressly
state that neither the fact of settlement nor the settlement agreement shall
constitute, or be construed or interpreted as, an admission by the Indemnified
Party of any issue, fact, allegation or any other aspect of the claim being
settled. No Indemnified Party shall pay or voluntarily permit the determination
of any liability which is subject to any such action while the Indemnifying
Party is negotiating the settlement thereof or contesting the matter, except
with the prior written consent of the Indemnifying Party, which consent shall
not be unreasonably withheld or delayed. In addition, Interpharm shall not
settle any Tris Infringement Claim with respect to which it has initiated
prosecution without the written consent of Tris, which shall not be unreasonably
withheld. Notwithstanding anything to the contrary contained in this Agreement,
Interpharm shall not be obligated to continue with any litigation or arbitration
that it has initiated or has begun the defense of if, in its sole and absolute
discretion, it believes that it is not advisable to continue with such
litigation.

                                    ARTICLE X

                                  MISCELLANEOUS

      10.1. Independent Contractor. It is understood that each Party is acting
as an independent contractor for its own account and this Agreement does not
establish a joint venture, agency, partnership or employer/employee relationship
between the Parties. Neither Party shall have authority to conclude contracts or
otherwise to act for or bind the other Party in any manner.

      10.2. Notices. All notices or other communications given pursuant hereto
by one party hereto to the other party shall be in writing and deemed given (a)
when delivered by messenger, (b) when sent by telecopier, (with receipt
confirmed), (c) when received by the addressee, if sent by Express Mail, Federal
Express or other express delivery service (receipt requested), or (d) five days
after being mailed in the U.S., first-class postage prepaid, registered or
certified, in each case to the appropriate addresses and telecopier numbers set
forth below (or to such other addresses and telecopier numbers as a party may
designate as to itself by notice to the other party):

      If to Tris, to it at:

      Tris Pharma, Inc.
      2033 Route 130, Suite D, Monmouth Junction, NJ 08852

      Attention: Ketan Mehta

      Phone: 732-940-2800; Fax: 732-940-2855

      If to Interpharm, to it at:

      Interpharm, Inc.
      75 Adams Avenue
      Hauppauge, New York, 11788
      Attention: Mr. Bob Sutaria
      Facsimile: (631) 952-9587

                                       20
<PAGE>

      with a copy to:

      Guzov Ofsink Flink, LLC
      600 Madison Avenue, 22nd Floor
      New York, New York  10022
      Facsimile: (212) 688-7273

      10.3. Assignment. Neither Party shall, without the prior written consent
of the other Party having been obtained, assign or transfer this Agreement to
any person or entity, in whole or in part, provided that, each Party may assign
or transfer this Agreement to any affiliate or to any successor by merger of
such Party, or upon a sale of all or substantially all of such Parties assets,
provided that such assigning Party shall remain liable for its obligations
hereunder. All of the terms and provisions of this Agreement shall be binding
upon and inure to the benefit of and be enforceable by the Parties hereto and
their respective successors and assigns.

      10.4. Severability. If any portion of this Agreement is held invalid by a
court of competent jurisdiction, such portion shall be deemed to be of no force
and effect and the Agreement shall be construed as if such portion had not been
included herein, provided however, if the deletion of such provision materially
impairs the commercial value of this Agreement to either party, the Parties
shall attempt to renegotiate such provision in good faith.

      10.5. Entire Agreement. This Agreement attached hereto contain the sole
and entire agreement and understanding of the parties hereto and their
respective affiliates and representatives related to the subject matter hereof
and supersede all oral or written agreements concerning the subject matter made
prior to the date of this Agreement.

      10.6. Amendment; Waiver. This Agreement cannot be amended, changed,
modified or supplemented orally, and no amendment, change, modification or
supplement of this Agreement shall be recognized nor have any effect, unless the
writing in which it is set forth is signed by Interpharm and Tris, nor shall any
waiver of any of the provisions of this Agreement be effective unless in writing
and signed by the party to be charged therewith. The failure of either Party to
enforce, at any time, or for any period of time, any provision hereof or the
failure of either Party to exercise any option herein shall not be construed as
a waiver of such provision or option and shall in no way affect that party's
right to enforce such provision or exercise such option. No waiver of any
provision hereof shall be deemed to be, or shall constitute, a waiver of any
other provision, or with respect to any succeeding breach of the same provision.

      10.7. Governing Law. This Agreement shall be governed by, and construed in
accordance with, the laws of the State of New York, as though made and to be
fully performed therein without regard to conflicts of laws principles thereof.

                                       21
<PAGE>

      10.8. Force Majeure.

            10.8.1 The obligations of the either Party hereunder shall be
suspended during the time and to the extent that such Party is prevented from
complying therewith due to any event or circumstances beyond the control and
without the fault or negligence of that Party so affected (which circumstance is
hereinafter referred to as "Force Majeure") including but not limited to
accidents, perils of navigation, floods, fire, storms, earthquakes, lockouts,
explosion, hostilities, war (whether declared or undeclared), civil
disturbances, order or acts of any government, whether de jure or de facto or
any official purporting to act under authority of any such government,
illegality arising from domestic or foreign laws or regulations, insurrections,
quarantine or custom restrictions, strikes, lockouts, or other labor difficulty
at the parties, or acts of God or other similar events beyond the reasonable
control of Interpharm or Tris resulting in hindrance of the performance by
either Party of its respective obligations hereunder.

            10.8.2 As soon as possible after being affected by a Force Majeure
circumstance, the Party so affected shall furnish to the other party all
particulars of the Force Majeure and the manner in which its performance is
thereby prevented or delayed. The Party whose obligations hereunder have been
suspended shall promptly and diligently pursue appropriate action to enable it
to lift the Force Majeure situation, except that party shall not be obligated to
settle any strike, lockout or other labor difficulty on terms contrary to its
wishes. In the event that a Force Majeure circumstance with respect to
Interpharm is not resolved within ninety (90) days, Tris shall have the right to
have the Product(s) which are adversely affected by the Force Majeure event
manufactured by a Second Source and share the net profits relating to such
Product(s) equally.

      10.9. Singular and Plural Forms. The use herein of the singular form shall
also denote the plural form, and the use herein of the plural form shall denote
the singular form, as in each case the context may require.

      10.10 Headings. The headings contained in this Agreement are for
convenience of reference only and shall not constitute a part hereof or define,
limit or otherwise affect the meaning of any of the terms or provisions hereof.

      10.11 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which, when
taken together, shall constitute one and the same instrument.

      10.12 Arbitration. Only disputes arising under Sections 2.8.1.1, 3.1.4 or
4.4 of this Agreement shall be arbitrable. The Parties hereby agree that any
other dispute arising under this Agreement shall not be submitted for
arbitration and shall not be arbitrable.

                                       22
<PAGE>

      IN WITNESS WHEREOF, the parties have caused this Manufacturing and Supply
Agreement to be executed by their respective duly authorized officers as of the
date first above written.

                                         INTERPHARM, INC.

                                       By:  /s/ Bob Sutaria
                                           -------------------------------------
                                           Bob Sutaria, President

                                       TRIS PHARMA, INC.

                                       By:  /s/ Katan Mehta
                                           -------------------------------------
                                           Ketan Mehta, CEO and President

                                       23AMENDMENT

      THIS AMENDMENT ("Amendment") is made and entered into as of July 6, 2005,
by and between Interpharm, Inc., having its principal place of business at 75
Adams Avenue, Hauppauge, New York, 11788 ("Interpharm"), and Tris Pharma, Inc.,
having its principal place of business at 2033 Route 130, Suite D, Monmouth
Junction, NJ 08852 ("Tris").

                              W I T N E S S E T H :

      WHEREAS, on February 24, 2005, Interpharm and Tris entered into an
agreement whereby Tris is to transfer certain research and technology to
Interpharm which it will use to develop and manufacture certain solid oral
dosage pharmaceutical products (the "Solids Agreement"); and

      WHEREAS, Interpharm and Tris desire to amend the Solids Agreement to add
certain pharmaceutical products;

      NOW, THEREFORE, in consideration of the premises herein contained and
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties, intending to be legally bound, agree as
follows:

                                    ARTICLE I

                                    AMENDMENT

      1. Amendment to Exhibit A. Exhibit A of the Solids Agreement shall be
amended with the addition of the following products:

      2. Amendment of Article I. Section 1.32 of the Solids Agreement shall be
deleted and replaced with the following:

      1.32 "Products" shall mean the generic finished dosage pharmaceutical form
      of the Products listed on Exhibit A annexed hereto, as may be amended from
      time to time.

            The following shall be added to Article I of the Solids Agreement:

      1.50 "Additional Product Payments" shall mean the aggregate of the
      _____________ Softgel Payments, the _____________ Payments and the Second
      Softgel Payments.

      1.51 "Additional Products" shall mean the generic finished dosage
      pharmaceutical form of the Products listed as number 8, 9 and 10 on
      Exhibit A, as amended by the Amendment.

      1.52 "Amendment" shall mean the July 6, 2005 Amendment to this Agreement.

<PAGE>

      1.53 "___________Softgel Payments" shall mean a payment of $125,000 to
      Tris upon execution of the Amendment to this Agreement and another payment
      of $125,000 to Tris upon successful completion of a bioequivalency study
      with respect to ___________ Softgel.

            For the sake of clarity, throughout this Agreement, "successful
      completion" shall mean completion of a bioequivalency study wherein i) the
      results demonstrate bioequivalence as defined by the FDA and ii) meet the
      requirements for filing an ANDA.

      1.54 "Initial Products" shall mean the Products listed on Exhibit A of the
      Solids Agreement prior to the Amendment.

      1.55 "___________Payments" shall mean the following: (i) a payment of
      $125,000 to Tris no later than two weeks after execution of the Amendment,
      in the event that Interpharm decides to proceed with _____________ in
      accordance with the terms of this Agreement; (ii) a second payment of
      $125,000 to Tris upon successful completion of a bioequivalency study with
      respect to _____________; and (iii) a payment of $125,000 upon receipt of
      final FDA approval of a _____________ ANDA. Should Interpharm decide not
      to proceed with _____________, (i) it shall not be deemed to be included
      as a Product under this Agreement, (ii) Interpharm shall not owe Tris any
      money for _____________, and (iii) Tris may develop ___________ with a
      third party.

      1.56 "Second Softgel" shall mean the Product listed as number 10 on
      Exhibit A, as amended by the Amendment.

      1.57 "Second Softgel Payments" shall mean a payment of $125,000 to Tris no
      later than the date on which Interpharm notifies Tris in writing of the
      designation of the Second Softgel (the "Second Softgel Notice").

      3. Amendment of Section 1.44.Section 1.44 of the Solids Agreement shall be
deleted and replaced by the following:

      1.44 "Total Tris Payments" shall mean the Initial Payment, plus the total
      of all of the Quarterly Payments, plus the total of the Additional Product
      Payments, as of a particular date.

      4. Amendment of Section 2.1.1. The second sentence of Section 2.1.1 of the
Solids Agreement shall be deleted and replaced with the following:

      "Tris shall deliver the Development Schedule for each of the Initial
      Products by April 1, 2005, for __________ Softgel and ___________, by the
      date of execution of the Amendment, and for the Second Softgel, within
      thirty (30) days of Tris' receipt of the Second Softgel Notice."

      5. Amendment of Section 2.2. (a) The first sentence of Section 2.2 of the
Solids Agreement shall be deleted and replaced by the following:

                                       2
<PAGE>

      "By April 1, 2005, Tris shall deliver to the PMC and Interpharm the
      Development Schedule for each of the Initial Products for their review and
      Interpharm's approval. Tris shall deliver to the PMC and Interpharm, for
      their review and Interpharm's approval, the Development Schedule for
      _______ Softgel and ____________ by the date of execution of the
      Amendment, and for the Second Softgel, within thirty days of Tris' receipt
      of the Second Softgel Notice."

      (b) The second sentence of Section 2.2 of the Solids Agreement shall be
amended by deleting the first word, and replacing it with the following:

      "With the exception of the Additional Products, in"

      6. Amendment of Section 2.7.1. The following shall be added as a second
      paragraph to Section 2.7.1:

      "In the case of _____________ Softgel, the exclusivity referred to in the
      preceding paragraph shall apply only to the manufacture, supply, marketing
      and distribution of _____________ Softgel for the generic prescription and
      generic over-the-counter markets. Tris' commitment, and Interpharm's
      rights, with respect to the branded prescription and branded
      over-the-counter markets shall be non-exclusive, meaning that Tris shall
      have the right to cooperate with any other person or entity with respect
      to the manufacture, supply and/or distribution of _____________ Softgel
      for the branded prescription and/or branded over-the-counter markets
      without the prior consent of Interpharm and Interpharm shall have no
      rights with respect to any sales resulting therefrom. Notwithstanding
      anything to the contrary contained herein, if _____________ Softgel is
      sold generically within the Territory by a third party with whom Tris has
      any direct or indirect agreement with respect to the sale of _____________
      Softgel, Interpharm shall still maintain all its rights as set forth in
      the preceding paragraph, even if such direct or indirect agreement was
      entered into in compliance with this paragraph."

      7. Amendment of Section 2.8.1.1. Section 2.8.1.1 of the Solids Agreement
shall be deleted and replaced by the following:

                  "Making the following payments to Tris. In the event that
            Interpharm fails to make any of the following payments, Tris's sole
            remedy shall be the commencement of an arbitration in accordance
            with Section 8.2:

                  2.8.1.1.1 the Initial Payment;

                  2.8.1.1.2 the Quarterly Payments; and

                  2.8.1.1.3 the Additional Product Payments."

      8. Additions to Section 2.8. The following shall be added as Section
2.8.1.12 of the Solids Agreement:

                                       3
<PAGE>

      "2.8.1.12 Notifying Tris, in writing, whether it wishes to proceed with
      _____________ within fourteen (14) days of Interpharm's receipt of
      _____________ Preliminary Product Details. In furtherance thereof, on the
      date of the Amendment, but not later than 48 hours after said date, Tris
      shall deliver to Interpharm's in-house intellectual property counsel ("IP
      Counsel") as many of the Product Details that Tris may have in its
      possession, as of such delivery date, with respect to _____________ (the
      "_____________ Preliminary Product Details"). Such disclosure shall be
      made by Tris based on Interpharm's assurances and agreement that (i)
      Interpharm's IP Counsel may use and evaluate such _____________
      Preliminary Product Details to provide an opinion and recommendation to
      Interpharm but shall not disclose any of the _____________ Preliminary
      Product Details to anyone within or outside Interpharm, except
      Interpharm's outside patent counsel, prior to Interpharm's notification of
      its decision on whether to proceed with Tris' _____________ and (ii) if
      Interpharm decides not to proceed with _____________, Interpharm's IP
      Counsel will return the _____________ Preliminary Product Details to Tris
      and shall not keep any copies thereof or any notes thereon. In the event
      that Interpharm, in its sole and absolute discretion, decides not to
      proceed with _____________, it shall not be responsible to make the
      _____________ Payments as is set forth in Section 1.55. In addition,
      nothing in this Agreement shall prevent Interpharm from developing,
      manufacturing, selling, marketing or distributing _____________ on its own
      in the future so long as Interpharm does not improperly use any
      Confidential Information of Tris. In such event, however, prior to
      submitting a _____________ ANDA to the FDA, Interpharm shall disclose
      under strict confidentiality its _____________ formula to Tris in
      sufficient detail to enable Tris to determine whether that formula is
      based in whole or in part on Tris' Confidential Information. If Tris
      reasonably believes that Interpharm's formulation is so based, nothing in
      this Agreement shall prevent Tris from seeking an injunction to block
      Interpharm from submitting the ANDA and/or from commercializing that
      _____________ product."

      9. Amendment of Section 3.1. The first sentence of Section 3.1 of the
      Solids Agreement shall be deleted and replaced with the following:

      "The Parties hereby agree, that for the purpose of clarity, Net Profits
      shall be calculated separately for each of (i) _______________, (ii) the
      Additional Products as a group and (iii) the Non-DS Products (as defined
      below) as a group."

      10. Amendment of Section 3.1.3.1. Section 3.1.3.1 shall be amended by
      deleting the first seven (7) words and replacing them with the following:

      "With respect to all Products other than the Additional Products and"

      A second paragraph shall be added to Section 3.1.3.1 and read as
      follows:

                                       4
<PAGE>

      "With respect to the Additional Products, the Set Aside shall be
      distributed to the Parties pro rata based on each Party's share of the
      aggregate of all of the Additional Product Payments, Development Costs and
      the Tris Reimbursable Set Aside for the Additional Products until the
      aggregate of the Set Aside for the Additional Products is equal to the sum
      of the Additional Product Payments plus all Development Costs plus the
      Tris Reimbursable Set Aside relating to the Additional Products."

      11. Amendment of Section 3.1.3.2. Section 3.1.3.2 of the Solids Agreement
      shall be amended by adding a second sentence as follows:

      "After the Set Aside, each Party shall be entitled to 50% of the remaining
      Net Profits, if any, from the sales of Additional Products, with the
      exception of _____________ Softgel, for which Interpharm shall be entitled
      to 60% of the remaining Net Profits and Tris shall be entitled to 40% of
      the remaining Net Profits."

      12. Amendment of Section 10.5. Section 10.5 of the Solids Agreement shall
be deleted and replaced by the following:

      "This Agreement, as amended by the Amendment, contains the sole and entire
      agreement and understanding of the parties hereto and their respective
      affiliates and representatives relating to the subject matter hereof and
      supersedes all prior agreements, understandings and arrangements, oral or
      written, between the parties concerning the subject matter hereof made
      prior to the date of this Agreement, as amended by the Amendment."

                                   ARTICLE II

                                  MISCELLANEOUS

      1. Amendments. The terms and provisions set forth in this Amendment shall
modify and supercede all inconsistent terms and provisions set forth in the
Solids Agreement. The parties agree that the Solids Agreement, as amended
hereby, shall continue to be legal, valid, binding and enforceable in accordance
with its terms.

      2. Survival of Representations and Warranties. All representations and
warranties made in the Solids Agreement shall survive the execution and delivery
of this Amendment.

      3. Headings. The section headings contained in this Amendment are for
purposes of convenience only, and shall in no way bear upon the construction or
interpretation of this Amendment.

      4. Modification and Waiver. This Amendment may not be modified or amended
except by an instrument or instruments in writing signed by the parties hereto.
No waiver of any of the provisions of this Amendment shall be deemed, or shall
constitute, a waiver of any other provisions, whether or not similar. No waiver
shall be binding unless executed in writing by the party making the waiver.

                                       5
<PAGE>

      5. Counterparts. This Amendment may be executed simultaneously in one or
more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

      6. Severability. The provisions of this Amendment are severable, and the
invalidity of any provision shall not affect the validity of any other
provisions.

      7. Binding Effect. This Amendment shall be binding upon, and shall inure
to the benefit of, the parties hereto and their respective successors and
permitted assigns.

                                       6
<PAGE>

      8. Governing Law. This Amendment, its validity, interpretation and
performance shall be governed by and construed in accordance with the internal
laws of the State of New York without giving effect to the conflict of laws
provisions thereof.

      IN WITNESS WHEREOF, this Amendment has been executed and is effective as
of the date first above-written.

                                        INTERPHARM, INC.

                                       By:  /s/ Bob Sutaria
                                           -------------------------------------
                                           Bob Sutaria, President

                                       TRIS PHARMA, INC.

                                       By:  /s/ Katan Mehta
                                           -------------------------------------
                                           Ketan Mehta, CEO and President

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]